Limosilactobacillus Reuteri + Setmelanotide
Setmelanotide brand name: Imcivree.
We found no known interaction between Limosilactobacillus Reuteri and Setmelanotide in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.
Limosilactobacillus Reuteri and Setmelanotide
We checked these two against our interaction database. Here is what we found.
No Known Interaction Found
We did not find a documented interaction between Setmelanotide and Limosilactobacillus Reuteri in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.
If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.
Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.
Limosilactobacillus Reuteri safety at a glance
Pregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center) — the full detail is in the Special populations card below. Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Limosilactobacillus Reuteri Does Interact With Other Medications
Limosilactobacillus Reuteri has 182 moderate known drug interactions in our database — Setmelanotide isn’t one of them. If you take anything else, check it against the full list below.
Check Another of Your Medications Against Limosilactobacillus Reuteri
We haven’t checked that one against Limosilactobacillus Reuteri yet — ask our pharmacists directly.
Covers the 2,830 medications we’ve checked against Limosilactobacillus Reuteri. Pick one to open its full report.
Limosilactobacillus Reuteri in Pregnancy & Breastfeeding
When used orally and appropriately.
When used orally and appropriately. Although clinical research during lactation is lacking, no safety concerns have been shown in clinical research involving infants up to 3 months of age.
DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.© 2026 Therapeutic Research Center
What Setmelanotide Is Prescribed For, and What Limosilactobacillus Reuteri Has Been Studied For
These two come up together because they touch the same health topic — not because they do the same job. Setmelanotide is a prescription medicine with approved uses on its FDA label. Limosilactobacillus Reuteri is a supplement: what follows is what researchers have looked at it for, and how strong that evidence is.
Setmelanotide is prescribed for: Imcivree is used to reduce excess body weight and maintain that weight loss long-term in adults and children with certain rare, specific causes of obesity. It is not intended for general weight loss or common obesity. Imcivree is approved for: acquired hypothalamic obesity (HO) in patients aged 4 and older; Bardet-Biedl syndrome (BBS) in patients aged 2 and older; and obesity caused by confirmed deficiencies of POMC, PCSK1, or LEPR genes (pathogenic, likely pathogenic, or uncertain-significance variants) in patients aged 2 and older.
Limosilactobacillus Reuteri has been studied for:
-
Obesity studied, not established Limosilactobacillus Reuteri has been studied for this. Natural Medicines rates the evidence: Insufficient Reliable Evidence To Rate Read what the research shows
Limosilactobacillus Reuteri for obesity
Although there has been interest in using oral Limosilactobacillus reuteri for obesity, there is insufficient reliable information about the clinical effects of L. reuteri for this condition.
Effectiveness ratings and the research summaries above are the verbatim record from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”. A rating below the top of that scale means researchers have looked at it — not that it works, and never that it can stand in for a prescribed medicine. Do not stop or replace Setmelanotide on your own; if you are taking Limosilactobacillus Reuteri for the same health topic, tell your prescriber, especially if the medicine is being adjusted to a target.
Where Limosilactobacillus Reuteri and Setmelanotide Sit Against Everything Else
Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.
#1,137 of 1,452 supplements looked up here in the last 7 days
#2,245 of 2,830 medications looked up here in the last 7 days
Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.
Where does our data come from?
- Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
- Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Limosilactobacillus Reuteri reference on this page ↓
- Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Limosilactobacillus Reuteri and Setmelanotide records this page draws on were last updated July 11, 2026.
- What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
About Limosilactobacillus Reuteri
What is Limosilactobacillus Reuteri?
- Infant colic
- Diarrhea (including antibiotic-associated)
- Digestive health
- Oral and gum health
- Constipation
- Immune support
Limosilactobacillus reuteri (formerly Lactobacillus reuteri) is a probiotic bacterium found in the human gut and certain fermented foods. It has the most supportive evidence for reducing crying in breastfed infants with colic and for some types of diarrhea, while many other uses remain unproven. It is generally well tolerated in healthy people, but people who are very ill or immunocompromised should talk to a doctor first.
Limosilactobacillus reuteri · Lactobacillaceae · Live bacterial cells (probiotic strains) · Chewable tablets, drops/oils, capsules, powders, fortified foods and yogurt
An interaction check asks whether these two react with each other — it does not ask whether Limosilactobacillus Reuteri is a good idea for someone in your situation. Here is what our Limosilactobacillus Reuteri record says about it on its own.
Limosilactobacillus Reuteri: dosing
There is no single official dose for L. reuteri. Do not assume a higher dose is better.
From our Limosilactobacillus Reuteri monograph — the full record covers uses, side effects and every documented interaction.
About Setmelanotide Injection
What Is Setmelanotide Injection Used For?
Brand name: Imcivree
Imcivree is used to reduce excess body weight and maintain that weight loss long-term in adults and children with certain rare, specific causes of obesity. It is not intended for general weight loss or common obesity.
Imcivree is approved for: acquired hypothalamic obesity (HO) in patients aged 4 and older; Bardet-Biedl syndrome (BBS) in patients aged 2 and older; and obesity caused by confirmed deficiencies of POMC, PCSK1, or LEPR genes (pathogenic, likely pathogenic, or uncertain-significance variants) in patients aged 2 and older.
Other Drugs & Limosilactobacillus Reuteri
Browse every other medication we’ve checked against Limosilactobacillus Reuteri — both the ones with a known interaction and the ones without. Select any drug for the full detail.
No drugs match “”.
182 interactions
- Metronidazole ›
- Doxycycline ›
- Erythromycin ›
- Minocycline ›
- Tetracycline ›
- Amoxicillin ›
- Ciprofloxacin ›
- Penicillin V Potassium ›
- Ampicillin ›
- Ceftazidime ›
- Clindamycin ›
- Penicillin G Potassium ›
- Cephalexin ›
- Dicloxacillin Sodium ›
- Nitrofurantoin ›
- Ofloxacin ›
- Rifampin ›
- Tobramycin ›
- Azithromycin ›
- Bacitracin ›
- Cefadroxil ›
- Cefuroxime ›
- Chloramphenicol ›
- Cloxacillin Sodium ›
- Dapsone ›
- Doxycycline Hyclate ›
- Erythromycin Ethylsuccinate ›
- Erythromycin Stearate ›
- Levofloxacin ›
- Neomycin ›
- Amikacin ›
- Cefaclor ›
- Cephradine ›
- Clarithromycin ›
- Cyclacillin ›
- Daptomycin ›
- Gatifloxacin ›
- Lincomycin Hcl ›
- Linezolid ›
- Methenamine Hippurate ›
- Methenamine Mandelate ›
- Minocycline Hydrochloride ›
- Norfloxacin ›
- Oritavancin Diphosphate ›
- Oxacillin ›
- Penicillin G Benzathine ›
- Retapamulin ›
- Trimethoprim ›
- Trovafloxacin ›
- Vancomycin ›
- Amoxicillin Veterinary ›
- Aztreonam ›
- Bacampicillin ›
- Benznidazole ›
- Capreomycin ›
- Carbenicillin Indanyl Sodium ›
- Cefamandole ›
- Cefazolin ›
- Cefdinir ›
- Cefditoren Pivoxil ›
Showing 60 of 182 moderate interactions — see all 182 on the Limosilactobacillus Reuteri page.
No interaction 2,647 drugs checked — show the list
We also checked Limosilactobacillus Reuteri against these medications and found no known interaction in our sources. Open any page to confirm.
- Apixaban ›
- Levothyroxine ›
- Amlodipine ›
- Methylphenidate ›
- Warfarin ›
- Sertraline ›
- Testosterone ›
- Losartan Potassium ›
- Metoprolol ›
- Ivermectin ›
- Aspirin ›
- Rivaroxaban ›
- Rosuvastatin ›
- Escitalopram ›
- Acetaminophen ›
- Tadalafil ›
- Clopidogrel ›
- Atorvastatin ›
- Docusate ›
- Abemaciclib ›
- Hydroxyurea ›
- Valacyclovir ›
- Ibuprofen ›
- Methamphetamine ›
- Semaglutide ›
- Sumatriptan ›
- Tirzepatide ›
- Warfarin Sodium ›
- Prednisone ›
- Propranolol ›
- Lisdexamfetamine ›
- Bupropion ›
- Metformin ›
- Lisinopril ›
- Bendamustine ›
- Acyclovir ›
- Amitriptyline ›
- Methotrexate ›
- Fluoxetine ›
- Acetaminophen, Codeine ›
- Lamotrigine ›
- Amphetamine ›
- Pregabalin ›
- Gabapentin ›
- Dextroamphetamine ›
- Isotretinoin ›
- Methylene Blue ›
- Clonazepam ›
- Omeprazole ›
- Amlodipine Besylate ›
- Quetiapine ›
- Duloxetine ›
- Letrozole ›
- Buspirone ›
- Naproxen ›
- Citalopram ›
- Bisoprolol ›
- Levothyroxine, Liothyronine ›
- Acetaminophen, Oxycodone ›
- Diazepam ›
Showing the 60 most looked-up of 2,647 medications checked with no known interaction — see the full Limosilactobacillus Reuteri list.
Limosilactobacillus Reuteri References
The 14 references that drive our Limosilactobacillus Reuteri monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
- Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010;126:e526-33.
- Savino F, Pelle E, Palumeri E, et al. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007;119:e124-30.
- Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
- Chau K, Lau E, Greenberg S, Jacobson S, Yazdani-Brojeni P, Verma N, Koren G.Probiotics for infantile colic: a randomized, double-blind, placebo-controlled trial investigating Lactobacillus reuteri DSM 17938. J Pediatr 2015;166(1):74-8. PubMed
- Indrio F, Di Mauro A, Riezzo G, Civardi E, Intini C, Corvaglia L, Ballardini E, Bisceglia M, Cinquetti M, Brazzoduro E, Del Vecchio A, Tafuri S, Francavilla R. Prophylactic use of a probiotic in the prevention of colic, regurgitation, and functional const
- Oncel MY, Sari FN, Arayici S, Guzoglu N, Erdeve O, Uras N, Oguz SS, Dilmen U. Lactobacillus Reuteri for the prevention of necrotising enterocolitis in very low birthweight infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2014;99(2
- Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, Heine RG, Stock A,Barr RG, Wake M. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014 1;348:g2107. PubMed
- Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind,placebo-controlled trial. J Pediatr. 2013;162(2):257-62. PubMed
- Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2020;127(2):275-284. PubMed
- Ojetti V, Gigante G, Gabrielli M, et al. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci. 2010;14(3):163-70.
- Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
- Sheyholislami H, Connor KL. Are probiotics and prebiotics safe for use during pregnancy and lactation? A systematic review and meta-analysis. Nutrients. 2021;13(7):2382. PubMed
- Yefet E, Colodner R, Strauss M, Gam Ze Letova Y, Nachum Z. A randomized controlled open label crossover trial to study vaginal colonization of orally administered Lactobacillus reuteri RC-14 and rhamnosus GR-1 in pregnant women at high risk for preterm la
Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
Taking Limosilactobacillus Reuteri and Setmelanotide Together: Common Questions
Is it safe to take Limosilactobacillus Reuteri with Setmelanotide?
Do Limosilactobacillus Reuteri and Setmelanotide have any of the same side effects?
Are Limosilactobacillus Reuteri and Setmelanotide used for the same thing?
Does Limosilactobacillus Reuteri interact with any other medications?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Keep Exploring
Still Have a Question About Setmelanotide and Limosilactobacillus Reuteri?
Our pharmacists answer your medication & supplement questions — free.
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.